Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

• US 5,508,260 A
• Filed: 06/10/1994
• Issued: 04/16/1996
• Est. Priority Date: 01/10/1991
• Status: Expired due to Term

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Young, Andrew A., Beaumont, Kevin
• Primary Examiner(s): Schain, Howard E.
• Assistant Examiner(s): Prickril, Benet
• Application Number:
  US08/259,755
• Time in Patent Office: 676 Days
• Field of Search: 514/4, 530/303, 530/307
• US Class Current: 514/6.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/23 Calcitonins
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

Methods for treatment of diabetes and other insulin-requiring conditions by administering insulin and a calcitonin with or without amylin, and methods for treatment of hypoglycemic conditions by administering a calcitonin alone or in combination with glucagon and/or an amylin, and related compositions.

Claims

1. A composition comprising a therapeutically effective amount of a calcitonin and an insulin admixed in a form suitable for therapeutic administration.

2. The composition of claim 1 wherein the effective amount of the calcitonin is about 0.01 mg to 1.0 mg.

3. The composition of claim 1 wherein said calcitonin is selected from the group consisting of calcitonins of avian origin and telost origin.

4. The composition of claim 1 wherein said calcitonin is chicken calcitonin.

5. The composition of claim 1 wherein the calcitonin is selected from the group consisting of eel calcitonin and salmon calcitonin.

6. The composition of claim 1 wherein the ratio of the therapeutically effective amount of the calcitonin and the therapeutically effective amount of the insulin is from about 1:

1 to about 1;

20.

7. The composition of claim 1 wherein said ratio is about 1:

10.

8. The composition of claim 1 further comprising an amylin.